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Abstract
The phosphopeptide P140 issued from the spliceosomal U1-70K snRNP protein is recognized by lupus CD4
+ T cells,
transiently abolishes T cell reactivity to other spliceosomal peptides in P140-treated MRL/lpr mice, and ameliorates their
clinical features. P140 modulates lupus patients’ T cell response ex vivo and is currently included in phase IIb clinical trials. Its
underlying mechanism of action remains elusive. Here we show that P140 peptide binds a unique cell-surface receptor, the
constitutively-expressed chaperone HSC70 protein, known as a presenting-protein. P140 induces apoptosis of activated
MRL/lpr CD4
+ T cells. In P140-treated mice, it increases peripheral blood lymphocyte apoptosis and decreases B cell,
activated T cell, and CD4
2CD8
2B220
+ T cell counts via a specific mechanism strictly depending on cd T cells. Expression of
inflammation-linked genes is rapidly regulated in CD4
+ T cells. This work led us to identify a powerful pathway taken by a
newly-designed therapeutic peptide to immunomodulate lupus autoimmunity.
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Introduction
The U1-70K small nuclear ribonucleoparticle protein is a major
spliceosomal autoantigen recognized in systemic lupus erythema-
tosus (SLE). We previously identified an epitope between residues
131–151 present within its RNA recognition motif and targeted
early during the progression of the disease by IgG antibodies and
CD4
+ lymph node cells (LNCs) from H-2
k MRL/lpr and H-2
d/z
(NZBxNZW)F1 lupus-prone mice [1,2]. A peptide analogue
phosphorylated on Ser
140 (named P140) was also recognized by
LN and peripheral MRL/lpr CD4
+ T cells [3]. Intravenous
administration into Fas(CD95)-deficient MRL/lpr mice of P140
significantly improved their clinical and biological manifestations
and prolonged their survival, while the non-phosphorylated
analogue did not [3]. Moreover, when incubated with lupus
patient’s peripheral blood lymphocytes (PBLs), P140 generated
secretion of high levels of regulatory cytokine IL-10 in cell cultures
without proliferation of CD4
+ T cells, suggesting that P140 (and
not the non-phosphorylated analogue, which induces CD4
+ T cell
proliferation) possesses specific immunomodulatory functions on
lupus T cells [4]. This assumption was supported by showing that
repeated administration of P140 into MRL/lpr mice transiently
abolishes T cell reactivity to other regions of the U1-70K protein
and to epitopes from other spliceosomal proteins [5,6] without
altering the capacity of P140-treated mice to mount a normal
protective antiviral immune response [6]. P140 was successfully
included in a phase IIa clinical trial [7], and is currently evaluated
in a phase IIb, double-blind, placebo-controlled dose-ranging
study.
The present study was performed to decipher the P140 mode of
action. We sought putative receptor(s), different from the MHC
molecules, which might explain the remarkable in vivo efficacy of
P140, either alone or synergistically with class II MHC-peptide-T
cell receptor (TCR) interaction. This led us to identify at the
surface of spleen cells and LNCs a very specific P140-receptor, the
heat-shock cognate HSC70 protein, and to further investigate
whether the P140 phosphopeptide acts via cd T cells. These
regulatory T cells, which control ab T cells, activated B cells and
NK cells, preferentially respond to phospholigands [8] and interact
with HSC70 [9,10]. They are abnormally regulated in human and
murine lupus [11,12]. We also examined the genes that are
differentially expressed rapidly after P140 administration into
MRL/lpr mice. The results indicate that P140 controls the lupus
disease by a unique mechanism involving pathways of both innate
and acquired immune responses.
Results
P140 recognizes cell surface-expressed HSC70 protein
To identify putative cell-surface receptor(s) of P140, we
undertook a series of experiments based on a previously described
method [13,14] using spleen cells and LNCs from MRL/lpr mice
and biotin-labeled P140. The purified proteins were subjected to
SDS-PAGE in denaturing conditions and the resolved gel was
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single specific protein band (Figure 1A), which was identified by
nano LC-MS/MS [15] as the heat-shock cognate 71-kDa protein,
also termed HSC70 or Hsp/HSC73 protein (Figure S1). Twenty-
six unique peptides matched between this newly characterized
P140-receptor and HSC70 covered 58% of the theoretical HSC70
sequence. Identification of several discriminating peptides allowed
us to clearly discard other Hsps, such as the inducible Hsp70/
Hsp72. HSC70 recovered from the cell surface in these conditions
was the only protein specifically bound by P140 in a dose-
dependent manner (Figure 1A). HSC70 also formed a stable
complex with the non-phosphorylated peptide 131–151 but not
with the scrambled peptide P140 (ScP140; Figure 1A). Formation
of the complex was hampered by competing P140 (Figure 1A).
To assess P140 binding to HSC70, we investigated the binding
parameters and kinetics by surface plasmon resonance. HSC70
was immobilized onto the sensor chip via one of its four thiol
groups, and different concentrations of P140 and 131–151
peptides were injected in the flux followed by a dissociation phase
(see the overlay surface plasmon resonance plots of the raw data in
Figure 1B). The association rate constants (kon) and dissociation
rate constants (koff) were 530 M
21s
21 and 3.88610
23s
21 for the
Figure 1. Peptide P140 binds the constitutively-expressed chaperone HSC70 protein (A) Biotin-labeled P140 and 131-151 peptides
form a stable and specific, dose-dependent complex with HSC70 expressed on the surface of CBA/J and MRL/lpr splenocytes. The
same results were obtained with LNCs from normal and lupus mice. There is no binding when a biotin-labeled scrambled form of P140 peptide
(ScP140 Btn) is used instead of P140 peptide, and the binding is inhibited by an excess of free, non-biotinylated peptides (see the quantification by
densitometry). (B) Direct binding to recombinant HSC70 protein of P140 and non-phosphorylated 131–151 peptides used at increasing
concentrations (1.56 to 12.5 mM), as measured by surface plasmon resonance experiments. Analysis was performed using the simple 1:1 Langmuir
binding model, the fitting to each model was judged by the x
2 value and randomness of residue distribution was compared to the theoretical model.
(C) Subcellular localization of HSC70 shown by immunoelectron microscopy. Fixed and permeabilized MRL/lpr PBLs were incubated overnight with
the anti-HSC70 rat monoclonal antibody 1B5, followed by incubation with goat anti-rat IgG conjugated to ultra-small gold particles. Gold particles
were enhanced using a silver kit. Cells were then treated for transmission electron microscopy with conventional methods (bar=500 nm). (D) Co-
localization, at the surface of non-permeabilized MRL/lpr splenocytes, of P140 peptide and HSC70 staining as shown by fluorescent microscopy: P140
followed using biotinylated peptide and FITC-labeled streptavidin, and HSC70 followed using the R-phycoerythrin-labeled anti-HSC70 rat monoclonal
antibody 1B5. DAPI (49,69-diamidino-2-phenylindole) was used to label the nucleus (bar=3 mm). (E) Binding in a dose-dependent manner of biotin-
labeled P140 peptide (but not of ScP140 Btn) to the surface of MRL/lpr splenocytes as measured at 4uC by FACS analysis (the results obtained at 20
and 37uC are shown in Figure S4). (F) Cell-surface HSC70 expression among different CBA/J (black line) and MRL/lpr (red) cell subsets. (1)
B220
+TCRb
2=B cells; (2) B220
+TCRb
+=activated T cells frequent in lupus mice, including CD4
2CD8
2 (DN) T cells, the number of which is raised in
MRL/lpr mice; (3) B220
2TCRb
2=naive cells; (4) B220
2TCRb
+=T cells. Binding visualized with an isotypic control antibody is shown (right panel, in
green).
doi:10.1371/journal.pone.0005273.g001
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21s
21 and 4.07610
23s
21 for the peptide
131–151, respectively, using Langmuir’s one site model, which
gave the best fit at all concentrations used (x
2=3.2/Rmax=75RU
and 28.0/Rmax=236 RU, for the P140 and 131–151 peptides,
respectively). The equilibrium dissociation constant (Kd) calculat-
ed from the ratio of the kinetic rate constants (kon/koff), was
7.32 mM and 6.72 mM, respectively, for the P140 and 131–151
peptides. Similar data were obtained when biotinylated P140 was
on the chip and HSC70 in solution. Thus, in this in vitro system,
both peptides bind with medium affinity (mM range) to HSC70.
ScP140 did not bind HSC70. Of significant importance, no
binding was observed between P140 and Hsp70.
In good agreement with previous data showing that HSC70 is
located at the plasma membrane, in the cytoplasm and nucleus
[16,17], a membrane and punctuated intracellular fluorescent
labeling of anti-HSC70 antibodies was observed on permeabilized
MRL/lpr (Figure S2) and CBA/J splenocytes and PBLs. By
electron microscopy, HSC70 was found localized in association
with the plasma and nuclear membranes, the endoplasmic
reticulum, small vesicles and the nucleus (Figure 1C). After
incubating non-permeabilized splenocytes of both strains with
P140, HSC70 and P140-staining co-localized at the plasma
membrane (Figure 1D; Figure S3).
Binding of P140 at the cell surface was confirmed by FACS
analysis using freshly purified MRL/lpr splenocytes, increasing
concentrations of biotin-labeled P140 and allophycocyanin-labeled
streptavidin to reveal interaction. Surface P140 staining increased
in a concentration-dependent manner at 4uC (Figure 1E) and
20uC (Figure S4), while very little staining was seen at 37uC, which
is consistent with the internalisation of P140 associated with its
HSC70 receptor. No fluorescence staining was visualized in the
presence of biotin-labeled ScP140.
HSC70 staining was present at the surface of MRL/lpr and
CBA/J TCRb
+B220
+/2 and TCRb
2B220
+/2 cells corresponding
to B cells, T cells and CD4
2CD8
2B220
+ double negative (DN) T
cells that progressively invade MRL/lpr mice (Figure 1F). Levels
of HSC70 expression at the surface of normal and MRL/lpr PBLs
were similar (6-week-old mice).
Structural and physical properties of P140 peptide
The above-described results show no difference regarding
HSC70 recognition by the phosphorylated andnon-phosphorylated
peptides. Knowing that only P140 controls lupus disease in MRL/
lpr mice, we evaluated conformational characteristics of both
peptides by
1H-NMR spectroscopy and molecular dynamics
calculation. The detailed determination of the peptide structures
is described in the supporting information (Tables S1, S2, S3, S4,
and Figures S5, S6, S7, S8). As shown in Figure 2A and 2B, the
conformation of the non-phosphorylated and phosphorylated
peptides appears only slightly different (see Text S1). It should be
emphasized in particular that in both peptide analogues, the side-
chain of the Ser
140 and pSer
140 residues is directed towards the
exterior medium and is part of the hairpin loop, which is probably
important for recognition properties.
The solubility of P140 and 131–151 peptides was determined at
20 and 37uC using dynamic light scattering measurements [18].
While a 200 mM-solution of peptide 131–151 remained highly
soluble in water, phosphate-buffered saline (PBS) and culture
medium (Figure 2C), aggregates form in the P140 solution at
concentrations equal or superior to 50 mM in culture medium and
PBS. In water, P140 was highly soluble (Figure 2C). The integrity
of P140, as measured in saline and PBS by high-performance
liquid chromatography from the area of the peak corresponding to
the intact peptide, remained intact during at least 60 days at 37uC
(Figure 2D).
Ex vivo, P140 induces apoptosis of specific T cell subsets
via a granzyme B-dependent mechanism
We wondered whether the beneficial P140 effect was mediated
by apoptosis of specific T cell subsets. We found ex vivo that after
P140 co-incubation, in a peptide dose- and time-dependent
manner, MRL/lpr PBLs displayed an apoptotic phenotype
(annexin V positivity, reduction of DIOC6 dye uptake; Figure 3A
and 3B; Figures S9, S10). Both MRL/lpr CD4
+ and CD8
+ T cells
underwent specific apoptosis. Specific lysis of MRL/lpr CD4
+ and
CD8
+ T cells was granzyme-B and caspase-dependent, while
perforin inhibitor had very little effect (Figure 3C; inserts c1,c2).
The number of viable B220
2CD138/Syndecan-1
+ plasma cells of
the B cell lineage also decreased in the MRL/lpr PBL fraction
(Figure 3D). Virtually no effect was observed when MRL/lpr PBLs
were incubated with the non-phosphorylated or the ScP140
peptides, and no P140 effect was detectable with CBA/J PBLs
(Figure 3A). No effect either was observed on murine CD4
+CD8
+
lymphoma T cells T29 (Figure 3E) and NIH 3T3 murine
fibroblasts (not shown).
It is noticeable that after a 20h-incubation of PBLs with P140
peptide, the proportion of preapoptotic CD4
+ activated blasts
(bearing the B220/CD45R marker [19]) significantly increased in
the culture (Figure 3F). No effect was measurable with peptide
131–151. The results shown with CD8
+B220
+ activated blasts
were not statistically significant (Figure 3F).
In vivo, P140 induces PBLs apoptosis via a mechanism
mediated by cd T cells
Next, we investigated in vivo the P140 effect on lymphocyte fate.
It is well documented that compared to normal situation, MRL/
lpr T and B cells are less sensitive to apoptosis, a feature resulting
from defective activation-induced cell death, which is a FasL-
dependent pathway [20–22]. It was therefore important to
examine in vivo the effect of P140 administration on the apoptosis
level of different lymphocyte subsets. After P140 administration
into MRL/lpr mice according to our standard protection protocol
[3], we found that at week 14 the absolute number of total
peripheral white cells, the number of which is raised in MRL/lpr
mice compared to CBA/J mice, was similar to the one measured
in non-autoimmune mice (Figure 4A). At week 7 (i.e. at the onset
of the disease) no difference was visible; at week 21 (eight weeks
after the last administration) the effect was no longer statistically
significant and this was true for all cell subsets axamined. The
proportions of living (annexin V
2) and apoptotic (annexin V
+) cells
were measured by FACS in haplotype-matched normal CBA/J
mice, MRL/lpr prone mice and P140-treated MRL/lpr mice
(Figure 4B). Compared to untreated MRL/lpr mice, the absolute
number of TCRb
+B220
2 and TCRb
+CD4
2CD8
2B220
+ viable T
cells, as well as that of B220
+TCRb
2 viable B cell population, was
diminished, at least until week 14 (Figure 4C–4E; Figure S11).
Regarding peripheral viable CD4
+B220
+ T cell blasts and CD8
+ T
cell population, their absolute number, which are increased in 14-
week-old MRL/lpr mice, clearly decreased in treated mice
(Figure 4F).
In the PBL fraction the proportion of apoptotic cells (diminished
in MRL/lpr mice, as expected) increased upon P140 peptide
treatment (Figure 4G). This effect was no longer visible at week 21.
Previous studies have shown that HSC70 expressed on the cell
surface of tumor cells might act as a loading molecule complexed
with cellular peptides for presentation to certain immune effector
P140 Peptide in Lupus
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that cd T cells interact with foreign and self-ligands, including
MHC and MHC-like molecules and non-peptidic phosphoanti-
gens [8,23]. We thus tested a pathway in which P140 likely
‘‘presented’’ by HSC70 induces apoptosis of potentially harmful
lymphocytes by a cd T cell-mediated mechanism. Nine-week-old
MRL/lpr mice received two successive intraperitoneal and
intravenous administrations of anti-pan TCR cd monoclonal
antibodies UC7-13D5 [24] eight and three days before P140
treatment. Efficiency of depletion was analyzed by FACS using
anti-pan TCR cd antibody GL3 [25]. In these conditions, the
number of viable cd T cells dropped over 54% (3.5 to 1.6%) in the
PBL fraction. The viable ab T-cell compartment was marginally
affected (62.7 to 69.2%). As shown in Figure 4H, while a single
intravenous administration of P140 into MRL/lpr mice induced
raised apoptosis of PBLs (27.6 vs. 10.1% annexin V
+ cells;
Figure 4H1), P140 induced no PBL apoptosis in cd T cell-depleted
MRL/lpr mice (16.1 vs. 15.1%; Figure 4H2). Similar results were
obtained in two independent experiments including each three
mice per group. These data clearly indicate that in vivo P140
induces PBL apoptosis via a mechanism involving cd T cells.
Several genes involved in inflammation are rapidly
down-regulated in CD4
+ T cells from P140-treated mice
In previous studies we found that P140 administration into
MRL/lpr mice transiently abolished T cell responsiveness to self-
CD4
+ T cell epitopes present in various spliceosomal proteins
[5,6]. Our experiments were thus designed to test whether in vivo
exposure to P140 might regulate expression of genes associated
with T cell tolerance and anergy. qPCR and dedicated arrays were
used to profile the expression of 84 genes related to T cell
tolerance (Figure 5A). Total RNA was extracted from LN non-
activated (B220
2) CD4
+ T cells (6-week-old mice) purified by
negative selection. Five house-keeping genes were used to
normalize the results and the whole experiment was repeated
Figure 2. NMR structure, solubility, and stability of P140 and 131–151 peptides. (A,B) Superposition of the four lowest energy structures of
the non-phosphorylated and phosphorylated peptides 131–151 after simulated annealing and restrained MD calculations. For simplicity, peptide
residues are numbered from 1 to 21 for the non-phosphorylated peptide (a) and phosphorylated P140 peptide (b). The phosphorylated Ser residue at
position 10 (Ser
140) is represented by pS. For full details, see Text S1, Tables S1, S2, S3, S4, and Figures S4, S5, S6, S7. (C) Determination of the solubility
limit of P140 and 131–151 peptides in distilled water, PBS and RPMI 1640 culture medium. The data show the variation of the mean intensity of light
scattered (expressed as kilocounts, Kcps) that occurs when peptide aggregates are formed. In culture medium, P140 peptide aggregates at
concentrations equal or superior to 50 mM. The amount and size of aggregates increase with peptide concentrations (413662800 nm at a 100 mM-
concentration and 697264200 nm at a 200 mM-concentration). (D) Stability at 37uC of P140 peptide in 150 mM NaCl and PBS, as measured by high-
performance liquid chromatography from the area of the peak corresponding to the intact peptide.
doi:10.1371/journal.pone.0005273.g002
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+ T cells, pdcd1, il2rb, stat3
and ctla4 gene expression was significantly up-regulated and
tnfrsf4 gene expression significantly down-regulated in MRL/lpr
CD4 T
+ cells of the same age (Figure 5A and 5B). Expression of
the 79 other genes was not significantly affected (P.0.05). After a
single intravenous administration of P140 into MRL/lpr mice,
expression of several genes was down-regulated (Figure 5A and
5C). Thus, pdcd1 gene expression, which was increased in MRL/
lpr mice, was significantly down-regulated 6h only after P140
administration (P=0.03). This feature was confirmed by FACS in
showing an increased number of CD4
+ T cells expressing
PDCD1/PD-1 in MRL/lpr mice, as compared to CBA/J mice
(Figure 5D), and a decreased expression level of PDCD1/PD-1
subsequent to a single P140 injection into MRL/lpr mice
(Figure 5D). Post-P140 injection, other genes were either
significantly down-regulated (il5 and il15, csf2, tnfsf10, cdk4,
icam1, foxp2, and itch) or up-regulated (NFkb1 and stat6) in
MRL/lpr mice (Figure 5C).
Figure 3. Ex vivo effect of P140 peptide on MRL/lpr PBL apoptosis. (A) Induction of MRL/lpr and CBA/J PBLs apoptosis as measured by flow
cytometry after annexin V- allophycocyanin labeling. The effect of increasing concentrations of the three peptides P140, 131–151 and ScP140 was
assayed 20h after peptide incubation with cells. The results are expressed as the mean percentage (6SD) of specific apoptosis measured in three
independent experiments. The decreased effect visualized when using 80 mM P140 probably results from peptide aggregation. (B) The same
experiment was performed in measuring apoptosis of MRL/lpr PBLs by the decrease of mitochondrial Dym, as measured by a reduction of DIOC6 dye
uptake, in the presence of increasing concentrations of P140 peptide. (C) Induction of CD4
+ and CD8
+ T cell apoptosis by P140 peptide and effect of
granzyme-B, perforin and caspase inhibitors. Twenty hours after P140 incubation, cell death was determined by flow cytometry using an annexin V-
allophycocyanin labeling (see also insert c1). Granzyme-B inhibitor I (20 mMZ-AAD-CMK; see also insert c2), perforin inhibitor (5 nM concanamycin A)
and caspase inhibitors (20 mM Z-VAD-FMK) were added 30 min post-P140 incubation to analyze the involvement of these pathways. The results are
expressed as the mean percentage (6SD) of specific apoptosis measured in three independent experiments. P values were (1) ,0.0001; (2) 0.0002; (3)
non significant (ns); (4) ns; (5) 0.0003; (6) 0.0090. (D) Effect of P140 and 131–151 peptides on the viability of CD138
+B220
2 plasmocytes as measured
by flow cytometry 20h after MRL/lpr PBLs treatment. Plots are representative of three independent experiments. (E) Viability of murine lymphoma T
cells T29 studied by measuring mitochondrial reduction of 3-(4,5-dimethythiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
dye 24h post-treatment with increasing concentrations of P140 peptide and two unrelated peptides X and Y used as positive controls. (F) Effect of
P140 and 131–151 peptides on the B220 marker expression by CD4
+ and CD8
+ T cells. Expression of B220 was analyzed on these cells 20h after
adding P140 or 131–151 peptides. The results are expressed as the mean percentage of cell subpopulations measured in three independent
experiments. P values comparing CD4
+B220
2 and CD8
+B220
2 cells without or after P140 treatment were 0.059 and 0.0432, respectively. P values
comparing CD4
+B220
+ and CD8
+B220
+ cells without or after P140 treatments were 0.0364 and 0.1707, respectively. The other comparisons were
statistically non-significant.
doi:10.1371/journal.pone.0005273.g003
P140 Peptide in Lupus
PLoS ONE | www.plosone.org 5 April 2009 | Volume 4 | Issue 4 | e5273Discussion
This report defines a previously undescribed pathway taken by a
peptide to immunomodulate autoimmune response (diagrammed
in Figure 6). Key features of this pathway, as identified in MRL/
lpr mice, are (i) P140 binding to a unique receptor, the
constitutively-expressed HSC70 chaperone protein; (ii) involve-
ment of cd T cells in a granzyme B- and caspase-dependent
mechanism, leading directly or indirectly via cytotoxic effectors to
apoptosis of distinct (activated) T and B lymphocytes/blasts. In
parallel, an important effect is also observed on non-activated
CD4
+ T cells, as shown at the level of several genes involved in
inflammation, which are rapidly down- or up-regulated upon
P140 treatment. Several check-points are decisive in this scheme
and might explain the remarkable protecting efficacy of P140 in
lupus. First, HSC70 but not inducible Hsp70 seems to operate as a
Figure 4. In vivo effect of P140 peptide on MRL/lpr PBL apoptosis. (A–H) Female MRL/lpr and CBA/J mice received peptide P140
intravenously (100 mg/mouse in saline) at weeks 5, 7, 9 and 13, according to our standard procedure [3]. Blue=CBA/J mice, orange=MRL/lpr mice,
red=P140-treated MRL/lpr mice. (A) The number of leukocytes/ml was evaluated by counting cells at weeks 7, 14 and 21. Each symbol represents the
absolute number of cells in one individual mouse (5 mice in each of the three groups). Horizontal bars represent the respective average values6SD.
(B–F) Influence of P140 therapy on the cell distribution. Detailed data observed at weeks 9, 12, 14 and 21 weeks are shown in the Figure S11. (B)
Different lymphocyte subpopulations present in the PBL fractions from CBA/J, MRL/lpr and P140-treated MRL/lpr mice evaluated by flow cytometry.
The gates used in the studies are shown in the inserts. (C) Number of B220
2TCRb
+ cells/ml in the peripheral PBL fraction collected from CBA/J, MRL/
lpr mice and P140-treated MRL/lpr mice, respectively at 14 and 21 weeks of age. P values were (1) 0.0011; (2) ns. (D) Number of B220
+TCRb
+ T cells/ml
in the peripheral PBL fraction collected from CBA/J, MRL/lpr mice and P140-treated MRL/lpr mice, respectively at 14 and 21 weeks of age. P values
were (1) 0.0084; (2) ns. (E) Absolute numbers of B220
+TCRb
2 cells in the peripheral PBL fraction collected from CBA/J, MRL/lpr mice and P140-treated
MRL/lpr mice, respectively at 14 and 21 weeks of age. P values were (1) 0.0059; (2) ns. (F) Number of CD4
+ and CD8
+ T cells/ml in the peripheral PBL
fraction collected from CBA/J, MRL/lpr mice and P140-treated MRL/lpr mice, respectively at 14 and 21 weeks of age. The number of CD4
+ and CD8
+ T
cells bearing the B220 marker is shown in gray. (G) Percentage of annexin V-allophycocyanin
+ PBLs collected from 9, 12, 14 and 21 week-old CBA/J
mice, MRL/lpr mice and P140-treated MRL/lpr mice. P values were (1) 0.0344; (2) 0.0051; (3) 0.0047; (4) ns, 0.8668. (H) PBL apoptosis measured after a
single intravenous administration of P140 peptide into MRL/lpr mice that received control hamster IgG (H1) or depleting cd T cell hamster IgG eight
and three days before P140 treatment (H2). cd T cell-depletion was achieved by two consecutive injections of 500 mg( 1
st administration) and 1 mg
(2
nd administration) of monoclonal antibody UC7-13D5 (half intraperitoneally and half intravenously). Sham depletion was performed with the same
amount of hamster IgG isotype. Efficacy of cd T cell depletion was measured by flow cytometry using anti-pan TCR cd hamster monoclonal antibody
GL3. Data reflect 3 mice per condition, and are representative of two separate experiments.
doi:10.1371/journal.pone.0005273.g004
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pound 15-deoxyspergualin has been shown to specifically bind to
HSC70, which among other effects inhibits NF-kB nuclear
translocation. It suppressed the progression of polyclonal B cell
activation and lupus nephropathy in MRL/lpr mice [26]. Ex vivo,
it altered the effective presentation of antigen to T cells by antigen-
presenting cells and changed the levels of cytokines produced after
engagement [27]. In a short trial, two of three treated SLE patients
showed non-severe infectious episodes after 15-deoxyspergualin
treatment [28].
Both P140 and 131–151 peptides (but not ScP140) bind to
HSC70 showing that the phosphoryl moiety does not alter
recognition and that sequence specificity exists. It has been shown
that HSC70 undergoes conformational changes upon binding
peptides [29]. An interesting issue would be to determine if HSC70
displays different conformations upon binding P140 and 131–151
peptides with a possible effect on recognition properties of the
resulting complex. HSC70 plays an important role in binding and
protectingpeptide for MHC class II molecules [30]. It interacts with
MHC molecules and particularly with HLA-DR4 [31]. Whether
this association is of central importance remains to be determined.
If the phosphoryl moiety has no obvious effect on the
recognition of peptide 131–151 by HSC70, it apparently
represents an important check-point in the P140 pathway for cd
T cell recognition. Thus, only P140 phosphoantigen presented in
the context of HSC70 could activate cd T cells. It is not known yet
if all cd T cell subsets can be activated by this new ligand. cd T
cells present an altered homing in lupus patients with an increased
Figure 5. P140-induced changes in expression of inflammation/tolerance/anergy-related genes in MRL/lpr mice. T cell anergy and
tolerance RT-PCR-Array were used to evaluate expression of a selected set of genes expressed by non-activated T CD4
+ cells from 6 week-old CBA/J
mice, MRL/lpr mice and P140-treated MRL/lpr mice. (A) Heat map of differentially-expressed genes between 6-week-old normal CBA/J and MRL/lpr
mice and between non-treated MRL/lpr and MRL/lpr mice that received each a single intravenous injection of 100 mg P140 peptide (evaluated 6 h
and 24 h post-administration). A scale of colour intensity is presented for each heat diagram. Red, up-regulation; green, down-regulation; black, no
change. Genes included in the microarray are listed in the table. Results are the average in gene expression for four independent experiments, with
three mice per group in each experiment. (B) Changes in gene expression between non-activated T CD4
+ cells from CBA/J and non-treated MRL/lpr.
Out of the 84 genes tested, four were significantly up-regulated and one significantly down-regulated. The other changes were not statistically-
significant. (C) Changes in gene expression between non-activated T CD4
+ cells purified from non-treated MRL/lpr mice and MRL/lpr mice collected 6
and 24h post-treatment. (D) PBL surface expression of PD-1 studied in the three groups of mice by flow cytometry. Mean fluorescence intensity (MFI)
values are indicated.
doi:10.1371/journal.pone.0005273.g005
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periphery, which in some studies correlate with disease activity
[32–34]. MRL/lpr mice lacking cd T cells develop more severe
disease [11]. Restoring cd T cell functions might therefore
constitute an important step [35]. Upon administration of P140
into MRL/lpr mice, activated T and B cells as well as DN T cells
were found to be engaged in an apoptotic process. This
observation is crucial in the P140 pathway since early mortality
of MRL/lpr mice is associated to T cell lymphoaccumulation
reminiscent of lpr-related lymphoproliferative disease. How cd cell-
mediated P140-induced killing precisely occurs remains to be
elucidated. Ex vivo, this Fas/FasL-independent process involves
granzyme-B and caspases but apparently not perforin. Knowing
that cd T cells express CD40, an important co-stimulation might
also occur via CD40L(CD154), which is expressed in a sustained
manner at the surface of lupus CD4
+ T cells and B cells [36].
CD16(FccRIII), the low affinity Fc receptor for IgG expressed by
cd T cells (and not by ab T cells), may also play an important role;
it was shown, for example, that soluble CD16 administered to
lupus mice after the onset of disease has a beneficial effect on their
biological and clinical behavior [37].
Although the absolute number of cd T cells is low in normal and
lupus conditions, this small population of regulatory cells exerts
numerous central effects [8,23]. Thus, upon activation, they might
influence dendritic cells, NK cells, ab T cells, and via either
contact-dependent mechanisms or chemiokine/cytokine secretion,
might contribute to tolerance restoration in P140-treated mice.
Beside this mechanism, which affects activated lymphocytes, P140
also alters properties of non-activated CD4
+ T cells. Thus,
hyperexpression in MRL/lpr mice of PD-1(CD279) molecule, a
member of the CD28 family, which is a hallmark of activated T
cells [38], is reversed in P140-treated mice. After P140 treatment
other genes were significantly up-regulated, such as genes coding
for STAT6 that promotes Th2-cell differentiation and NFkB1/
p50, or down-regulated, such as genes coding for adhesion
molecule ICAM-1, IL-15, IL-5 and CFS2 cytokines, transcrip-
tional regulator FOXP2, CDK4 (blocking the formation of cyclin-
D/CDK4 complexes in murine lupus was shown to inhibit
antigen-induced and anti-CD3-mediated splenic T cell prolifera-
tion as well as T-dependent B cell activation and proliferation in
vitro [39]), the E3 ligase Itch, and TNFSF10(TRAIL) (a member
of the TNF ligand superfamily, which exacerbates lupus [40]).
Figure 6. Proposed mechanisms underlying P140 peptide protective effect against disease in MRL/lpr mice. P140 physically associates
with a unique receptor, the constitutive HSC70 chaperone protein, which is present on a majority (if not all) of immune cells. The P140-HSC70
complex (but not the putative complex encompassing the non-phosphorylated peptide 131–151) directly or indirectly activates cd T cells. Via a
granzyme B- and caspase-dependent mechanism, apoptosis targeting activated CD4
+ T blasts, CD8
+ T cells, CD4
2CD8
2B220
+ T cells and B cells is
induced (directly or via another cytotoxic effector) leading to a diminution of T-cell help to B cells, a diminution of antigen-presenting cell activity by
B cells and a drop of antibody production by autoreactive B cells. In parallel, activated cd T cells secrete cytokines that modulate the ab T cell fate.
This model does not exclude the possibility that in parallel, P140 also induces anergy, deletion, or deviation of autoimmune T cells, via antagonism or
partial agonism of the ab T lymphocytes TCR [3]. In addition, P140 acts on non-activated CD4
+ T cells by altering several intracellular pathways,
leading, in particular, to dramatic effects on the NFkB and TNF pathways, and diminution of PD-1 expression, which is raised in MRL/lpr mice.
doi:10.1371/journal.pone.0005273.g006
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understand the precise signaling pathways induced upon P140
administration, these results show that in vivo P140 exerts a rapid
effect on genes involved in inflammation and can restore some
dysfunctions, as exemplified with PD-1.
In conclusion, we have demonstrated that in MRL/lpr mice
P140 binds to HSC70 and induces a novel regulatory circuit
involving cd T cells, which affects autoreactive T and B cell
survival. We thus propose a comprehensive mechanism triggered
by P140 to control the lupus disease in this mouse strain. In
addition, these findings shape our understanding of the immuno-
regulatory functions of cd T cells in autoimmune diseases.
Materials and Methods
Synthetic peptides
The synthesis and purification of P140 peptide (RIHM-
VYSKRpSGKPRGYAFIEY; produced under Good Manufactur-
ing Practice conditions), and of peptides 131–151 (RIHM-
VYSKRSGKPRGYAFIEY) and ScP140 (YVSRYFGpSAIR-
HEPKMKIYRG) were described previously [1,3,7]. For the
biotin-labeled peptides, the biotin moiety was introduced at the
end of peptide assembly as a Fmoc-Lys(biotin)-OH derivative.
Homogeneity of peptides was checked by analytical high-
performance liquid chromatography, and their identity was
assessed by matrix-assisted laser desorption and ionization time-
of-flight (TOF) mass spectrometry using a Protein TOF apparatus
(Bruker Spectrospin). The solubility limits of both peptides in the
cell culture medium RPMI 1640, PBS and distilled water were
determined at 20 and 37uC using dynamic light scattering
measurements [18].
1H-NMR experiments
D2O (99.8%) and trimethylsilyl-3-propionic acid-2,2,3,3-d4
(TSP-d4) were purchased from Euriso-top. Peptides 131–151 and
P140 (2 mM final) were dissolved in 0.6 mL of 95% H2O and 5%
D2O. The pH of the NMR sample was adjusted to 4.0. Spectra
were recorded at 4uC using a Bruker DRX600 NMR spectrom-
eter. All chemical shifts were referenced to methyl signals of TSP-
d4 as an internal standard. 2D TOCSY experiments [41,42] were
performed on each peptide with a mixing time, tm, of 20 and
70 ms. Four 2D-NOESY experiments with mixing times ranging
from 100 to 500 ms were performed. The build-up curve [43] for
different NOE correlations showed that spin diffusion was
negligible for tm=200 ms. The spectral width in F1 was
7200 Hz. Water resonance suppression in the TOCSY and
NOESY experiments was achieved using the water suppression by
gradient-tailored excitation (WATERGATE) sequence [44,45].
Data processing was performed using XWIN-NMR software.
Distance restraints for structural calculations were generated from
the NOESY spectra (tm=200 ms) using XEASY software [46]
and by classifying NOE cross-peaks as strong (1.8–2.5 A ˚), medium
(2.5–3.5 A ˚) and weak (3.5–5.5 A ˚) based on the volume of the
respective cross-peaks [47], calculated by taking as reference the
distance of 1.78 A ˚ between two non-equivalent geminal protons.
Molecular dynamics calculation
Energy minimization (EM) and molecular dynamics (MD)
calculations were performed on an Octane Silicon Graphics
workstation. The structure calculations were done by restrained
molecular dynamics in dihedral angle space using the standard
simulated annealing protocol, as implemented in the program
DYANA-1.4 [48] to generate, in a random way, a set of 100 initial
structures corresponding to the NMR constraints. The SA
protocol permits the exploration of the whole conformational
space to find the global minimum energy conformation of the
molecule and it has been shown to be a useful procedure for the
study of constrained systems [49–51]. Fifty structures with the
lowest energies were chosen for the refinement step with restrained
minimization. Each of them was submitted to 900 steps of
minimization (300 steps with steepest descent, 300 steps with
conjugate gradient and 300 steps with Newton-Raphson methods),
then to 35ps of MD in vacuo at 300K for equilibration and finally to
200ps of MD applying derived NMR restraints with a force
constant of 20 kcal mol
21 A ˚ 22. Conjugate gradient EM was
completed within 750 steps. The 50 refined structures were
evaluated with MOLMOL [52] as results. For MD and EM
calculations, the DISCOVER-3 module of the Insight II program
(Accelrys, Inc.) was used. Consistent-valence force field with a
default cut-off distance of 9.5 A ˚ and a distance-dependent
dielectric constant, equal to 4r, was applied to all peptides [53].
In order to avoid structural artefacts due to overestimation of
coulombic interactions in vacuo, the net electric charges of the N-
and C-terminal charged groups were neglected. The w angle for
the non-glycine L-residues was constrained between 2175u and
0u.
Identification of P140 receptor
The detection of cell surface protein(s) recognized by P140 was
adapted from a previously described method [54,55]. Total
splenocytes and LN cells from 7–8 week-old MRL/lpr or
unprimed CBA/J mice were isolated on nylon membrane
(100 mM). Cells (about 50610
6) were incubated for 1h at room
temperature (RT) in 5 mL of serum free RPMI 1640 culture
medium (Biomedia) containing biotin-labeled peptides (P140
peptide, peptide 131–151 or scramble P140 peptide). In some
experiments, unlabeled P140 peptide was added as a competitor.
After washing cells once in phosphate buffered-saline (PBS)
containing 1 mM EDTA, nucleus-free cell extracts were prepared
in lysis buffer E (20 mM Tris-HCl pH 7.5, 50 mM NaCl, 5 mM
MgCl2,1mL/1mL protease inhibitors from Sigma, 0.5% Triton
X100, 1 mM NaF, 1 mM Na3VO4). The complexes formed
between the biotin-labeled P140 and putative cell-surface
receptors were isolated by purification of the extracts using
100 mL avidin-agarose (ImmunoPure Immobilized Avidin, Pierce)
in PBS containing 1 mM EDTA, 1mM NaF, and 1 mM Na3VO4.
After overnight incubation at 4uC, the samples were washed
extensively with the same buffer. The purified proteins were
subjected to SDS-PAGE and revealed by colloidal blue staining.
The relative signal intensity of each band was quantified by
densitometry with the ImageJ 1.33u freeware (Gel Analyzer tool,
NIH) after scanning. The identification of HSC70 was deduced
from mass spectrometry analysis as described below after cutting
bands of interest.
Protein preparation for in-gel digestion
The gel pieces were successively washed with 50 mLo f2 5m M
NH4HCO3 and 50 mL of acetonitrile (three times), and dehydrat-
ed with 100 mL acetonitrile before reduction in the presence of
10 mM dithiothreitol in 25 mM NH4HCO3 (1h at 57uC) and
alkylation in the presence of 55 mM iodoacetamide in 25 mM
NH4HCO3. For tryptic digestion, the gel pieces were resuspended
in 2 volumes of trypsin (12.5 ng/mL; Promega V5111) freshly
diluted in 25 mM NH4HCO3 and incubated overnight at 37uC.
The digested peptides were then extracted from the gel in a
solution containing 34.9% H2O, 65% acetonitrile and 0.1%
HCOOH, and directly analyzed by nanoLC-MS/MS.
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The analysis was performed using a nanoACQUITY Ultra-
Performance-LC (UPLC; Waters). The samples were trapped on a
2060.18 mm, 5 mm Symmetry C18 precolumn (Waters), and the
peptides were separated on a ACQUITY UPLCH BEH130 C18
column (Waters), 75 mm6200 mm, 1.7 mm particle size. The
solvent system consisted of 0.1% formic acid in water (solvent A)
and 0.1% formic acid in acetonitrile (solvent B). Trapping was
performed during 3 min at 5 mL/min with 99% of solvent A and
1% of solvent B. Elution was performed at a flow rate of 400 nL/
min, using 1–40% gradient (solvent B) over 35 min at 45uC
followed by 65% (solvent B) over 5 min.
MS and MS/MS conditions on SYNAPT mass
spectrometer
The MS and MS/MS analyzes were performed using a
SYNAPT
TM apparatus, an hybrid quadrupole orthogonal accel-
eration time-of-flight (TOF) tandem mass spectrometer (Waters)
equipped with a Z-spray ion source and a lock mass system. The
capillary voltage was set at 3.5 KV and the cone voltage at 35 V.
Mass calibration of the TOF was achieved using phosphoric acid
(H3PO4) on the [50;2000] m/z range. Online correction of this
calibration was performed with Glu-fibrino-peptide B as the lock-
mass. The ion (M+2H)
2+ at m/z 785.8426 was used to calibrate
MS data and the fragment ion (M+H)
+ at m/z 684.3469 was used
to calibrate MS/MS data during the analysis.
For tandem MS experiments, the system was operated with
automatic switching between MS and MS/MS modes (MS 0.5 s/
scan on m/z range [250;1500] and MS/MS 0.7 s/scan on m/z
range [50;2000]). The three most abundant peptides (intensity
threshold 60 counts/s), preferably doubly and triply charged ions,
were selected on each MS spectrum for further isolation and CID
fragmentation with 2 energies set using collision energy profile.
Fragmentation was performed using argon as the collision gas.
The complete system was fully controlled by MassLynx 4.1 (SCN
566; Waters).
Data analysis and protein identification
Raw data collected during nanoLC-MS/MS analyses were
processed and converted with ProteinLynx Browser 2.3 (Waters)
into .pkl peak list format. Normal background subtraction type
was used for both MS and MS/MS with 5% threshold and
polynomial correction of order 5, and deisotoping was performed.
The MS/MS data were analyzed using the MASCOT 2. 2. 0.
algorithm (Matrix Science) to search against the UniProtKB/
Swiss-Prot database, version 54.8, concatenated with reversed
copies of all sequences (26349,480 entries). Spectra were searched
with a mass tolerance of 15 ppm for MS and 0.07 Da for MS/MS
data, allowing a maximum of one missed cleavage site by trypsin
and with carbamidomethylation of cysteine residues and oxidation
of methionine residues specified as fixed and variable modifica-
tions, respectively. Protein identifications were validated when at
least two peptides were found with Mascot ion score greater than
35 for each MS/MS spectrum.
For the estimation of the false positive rate in protein
identification, a target-decoy database search was performed.
Criteria used for protein identifications followed the general
guidelines for reporting proteomic experiments (MIAPE; http://
www.psidev.info).
Surface plasmon resonance analysis
BIAcore 3000 system (Biacore AB) was used to evaluate the
binding of P140 peptide to HSC70 protein. Sensor chip CM5,
surfactant P20, amine coupling kit containing N-hydroxysuccini-
mide (NHS) and N-ethyl-N9-dimethylaminopropyl carbodiimide
(EDC), 2-(2-pyridinyldithio)ethaneamine (PDEA) and ethanol-
amine were from Biacore AB. Biosensor assays were performed
with HBS-EP buffer as running buffer (10 mM HEPES, 150 mM
NaCl, 3 mM EDTA, 0.005% surfactant P20, pH 7.4). The
different compounds were diluted in the running buffer. The
sensor chip surface was regenerated after each experiment by
injecting 10 mL of 10 mM HCl. Recombinant bovine HSC70
(Stressgen) was immobilized on flow cells of a CM5 sensor chip
through its thiol groups using 35 mL PDEA in 50 mM borate
buffer, pH 8.3 on the NHS/EDC-activated matrix. Then, 35 mL
of HSC70 (100 mg/mL in formate buffer, pH 4.3) were injected
until a response of 13,000 response units (RU) corresponding to
13 ng/mm
2 of HSC70 was immobilized. Twenty mL of a 50 mM
cysteine/1 M NaCl solution was used to saturate unoccupied sites
on the chip. The direct binding measurement of P140 peptides to
HSC70 was carried out at 25uC with a constant flow rate of
20 mL/min. P140 peptide and analogues were injected in the flux
at different concentrations for 3 min, followed by a dissociation
phase of 3 min. The kinetic parameters were calculated using the
BIAeval 3.1 software on a personal computer. Analysis was
performed using the simple 1:1 Langmuir binding model. The
specific binding profiles were obtained after subtracting the
response signal from the control empty channel and from blank-
buffer injection. The fitting to each model was judged by the x
square value and randomness of residue distribution compared to
the theoretical model.
Immunofluorescence
To study the co-localization of HSC70 and P140 peptide
staining, freshly isolated splenocytes from MRL/lpr mice were
washed with PBS and incubated at RT for 45 min in PBS
containing 25 mM biotinylated P140. Cells were then washed
three times in Tris buffered-saline (TBS) and fixed for 1 h at RT in
4% paraformaldehyde (PFA) in 0.1M phosphate buffer (PB). Fixed
cells were incubated for 1h at RT with a rat monoclonal anti-
HSC70 antibody labeled with R-phycoerythrin (PE; 1:150; clone
1B5; Stressgen) in TBS containing 2% (w/v) BSA. After washing
in TBS, cells were incubated with fluorescein isothiocyanate
(FITC)-labeled streptavidin (1:400, Molecular Probes) and 49,69-
diamidino-2-phenylindole (DAPI, 1:1,000; Molecular Probes),
washed thrice in TBS and fixed for additional 1 h at RT in 4%
PFA in 0.1M PB. Control experiments were performed by
omitting biotinylated peptide. Samples were finally mounted on
slides using Dako’s fluorescence mounting medium. Pictures were
obtained with a Zeiss fluorescence microscope (Axiovert 200 M)
using an X63 magnification. Images were acquired with a digital
camera using Axiovision 4.37 software (Zeiss). Double immuno-
fluorescence images were obtained by superimposing two single-
color pictures with Adobe Photoshop 8.0. To study the localization
of HSC70 in permeabilized cells, see the legend of the Figure S2.
Immuno-electron microscopy
To study the subcellular localization of HSC70 by immunoelec-
tron microscopy, freshly isolated PBLs from MRL/lpr mice were
washed with PBS and fixed in 4% (v/v) PFA and 0.2% (v/v)
glutaraldehyde in 0.1M PBfor 1h at RT. Cells were embedded in 1%
agarose, permeabilized with 0.2% saponin for 10 min, washed and
saturated with 2% BSA and 0.2% (w/v) water fish skin gelatin
(WFSG,Sigma)inTBS before overnight incubation at 4uCw i t ha n t i -
HSC70 rat monoclonal antibody (1:200; clone 1B5; Abcam) in TBS
containing 0.2% BSA and 0.05% WFSG. Bound antibody was
visualized by preembedding labeling using goat anti-rat IgG
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containing 2% acetylated BSA (Aurion) and 0.2% WFSG. After
washing in TBS, cells were fixed in 1% glutaraldehyde, washed again
in TBS, and gold particles were enhancedusing a silver kit (HQsilver;
Nanoprobes). After further washing in 0.1M PB, cells were postfixed
for 10min in 0.5% OsO4, dehydrated in graded series of ethanol,
treated with propylene oxide and embedded in epon (Inland Europe).
Ultrathin sections were stained with uranyl acetate and lead citrate
and examined by TEM using a Hitachi H600 microscope. Images
were acquired using a CCD camera (Hamamatsu).
Cellular assays and FACS analysis
Lymphocytes from normal and lupus mice were purified by
density separation (Lympholyte-M, d=1.0875; Cedarlane). Periph-
eral blood lymphocytes (PBLs) were collected, washed 3 times in L-
alanyl-L-glutamine-enriched RPMI 1640 medium (Biomedia)
containing 10% fetal calf serum (FCS; Biomedia), 10 mg/mL
gentamycin, 10 mM HEPES, and 5610
25 M b-mercaptoethanol,
and resuspended at 1610
6 cells/mL in the above-described
medium. Cell death occurring in the presence of peptides was
measured in triplicate in a time scale of 30 min to 20 h using 1610
5
cells and 0–80 mM peptide/well. Apoptosis was measured by
double staining with allophycocyanin (APC)-labeled annexin V (BD
Bioscience) and propidium iodide using a FACSCalibur flow
cytometer (BD Biosciences) [56]. Apoptosis was also studied by a
decrease in mitochondrial transmembrane potential as detected by
the reduction of DiOC6(3) dye uptake [56]. For specific labeling the
following antibodies were purchased from BD Bioscience: FITC-
conjugated-B220- and TCRb-antibodies; PE-conjugated-CD4- and
CD138-antibodies; PerCP-conjugated-CD8- and B220-antibodies.
FITC-conjugated TCRcd and PD-1 antibodies were purchased
from eBioscience. PE-conjugated-HSC70-antibodies were pur-
chased from Stressgen. For testing the influence of apoptosis
inhibitors, the following inhibitors were incubated with cells for
30 min at 37uC: Granzyme B inhibitor I (20 mMZ-AAD-CMK;
Calbiochem), perforin inhibitor (5 nM concanamycin A; Calbio-
chem) and caspases inhibitors (20 mM Z-VAD-FMK; Promega).
Data acquisition and analysis were performed using BD Bioscience
CellQuest 3.3 software. Depending on the cell subsets studied,
between 20,000 and 100,000 events were acquired. Experiments
were repeated at least 3 times. Data are presented as mean6SD.
Statistical significance was determined by Student’s t-test. Differ-
ences were considered significant at P ,0.05.
FACS analysis of cell surface HSC70 expression
Splenocytes were washed in PBS and incubated for 20 min at 4uC
with biotinylated peptide diluted in PBS containing 2% (v/v) FCS at
the indicated concentrations.After washing, cellswere incubated with
APC-labeled streptavidin at 1 mg/mL in PBS containing 2% (v/v)
FCS at 4uC for 15 min before another wash and subsequent analysis
by flow cytometry. At least 20,000 events were acquired.
Transcriptomic assays
For monitoring the effect of P140 peptide on the expression of
focused gene panels linked to inflammation, P140 peptide (or PBS
as control) was administered intravenously into MRL/lpr and
CBA/J mice (100 mg in PBS/mouse/injection), and 6 and 24 h
post-treatment, T CD4
+ cells mRNA levels for 84 genes involved
in T cell anergy and 5 constitutive genes were measured using the
SuperArray quantitative PCR assay (SuperArray Cell Anergy and
Tolerance RT2 Profiler
TM PCR Array, Bioscience Corp). Briefly,
inguinal, popliteal, and periaortic LN from 6-week-old MRL/lpr
or CBA/J mice were removed 6 or 24 h after intravenous injection
with 100 mg P140 in PBS (3 mice) or PBS alone and washed in
L-alanyl-L-glutamine enriched RPMI 1640-Glutamax I (Life
Technologies) containing 10% FCS, 10 mg/mL gentamicin,
10 mM HEPES, and 5610
25 M 2-mercaptoethanol. LN cells
were then enriched for CD4
+ T cells by negative selection. LN
cells were depleted of macrophages, granulocytes, B cells, and
CD8
+ T cells by incubation with anti-CD11b (Mac-1), anti-GR1
(8C5), anti-CD19 (1D3), anti-B220 (6B2) and anti-CD8 (Lyt-2)
monoclonal antibody purified in-house and with magnetic beads
coupled to anti-rat immunoglobulins (Dynal). After negative
selection, greater than 95% of the resulting cells were CD4
+
positive by fluorescence-activated cell sorting analysis.
Total RNA was extracted from approximately 5610
6 TC D 4
+
cells using Qiagen RNeasyH mini kits with inclusion of a DNase
treatment step. First strand cDNA synthesis and quantitative real-
timePCRwithSYBRgreenmastermixwasperformedinStratagene
MX4000 Real Time PCR SystemH. In brief, cDNA was prepared
from 500 ng total RNA by using a RT2 PCR array first strand kit. A
total volume of 25 mL of PCR mixture, which included 12.5 mLo f
RT2 Real-Time SYBR Green/ROX PCR master mix from
SuperArrayBioscience containing HotStartDNApolymerase, SYBR
Green dye, and the ROX reference dye (Tebu-bio), 11.5 mLo f
double-distilled H2O, and 1 mL of template cDNA, was loaded in
each well of T cells Anergy and Tolerance RT2 Profiler PCR array
(SuperArray BioscienceH), according to the manufacturer’s instruc-
tions. PCRamplification was conducted with an initial 10 min step at
95uC followed by 45 cycles of 95uCf o r1 5sa n d6 0 uCf o r1m i n .T h e
fluorescent signal from SYBR Green was detected immediately after
the extension step of each cycle, and the cycle at which the product
was first detectable was recorded as the cycle threshold. Data were
imported into an Excel database and analyzed using the comparative
cycle threshold method with normalization of the raw data to
housekeeping genes including b-glucuronidase, hypoxanthine gua-
nine phosphoribosyl-transferase1, b-actin, Hsp90 and glyceralde-
hyde-3-phosphate dehydrogenase. Data were expressed as the
mean6SD of four independent experiments.
In vivo depletion of cd T cells
Hamster anti-pan TRC cd monoclonal antibodies (UC7-13D5
clone) were purified from hybridoma culture supernatants using
HiTrap protein G column (Pharmingen). cd T cell-depletion was
achieved by two consecutive injections of hamster monoclonal
antibodies (500 mg for the first administration and 1mg for the
subsequent one; half intraperitoneally and half intravenously) 8
and 3 days before P140 administration. Sham depletion was
performed with the same amount of hamster IgG isotype (The
Jackson Laboratory). MRL/lpr mice received P140 peptide
(100 mg/mouse) in saline via the intravenous route [3]. Flow
cytometry was used to monitor cd T cell depletion and ab T cell
number, and to measure PBL apoptosis.
Animal welfare
All experimental protocols were carried out with the approval of
the local Institutional Animal Care and Use Committee
(CREMEAS).
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